Cybin Therapeutics, ụlọ ọrụ bioscience na-ahụ maka ọgwụgwọ onwe ya na ebumnuche ịchọpụta na ịzụlite usoro ọgwụgwọ enyemaka psilocybin, enyela PEX010 (25 mg) ikike site na Filament maka ojiji na nnwale ahụ. A na-atụ anya na ikpe a ga-amalite na Q3'22 ga-agụnye ndị nwere nnukwu nsogbu ịda mbà n'obi bụ ndị na-enweta ọgwụgwọ serotonin reuptake inhibitor (SSRI), nke a na-ejikarị agwọ ịda mbà n'obi, yana ndị SSRI-naive.

"Nkwenye ahụike Canada bụ ihe na-egosi ma izi ezi nke nnwale a yana ikike Filament imepụta na inye ndị na-achọ ọgwụ maka ọkwa ọgwụ ọgwụ," ka Filament Chief Executive Officer, Benjamin Lightburn kwuru. "Mmetụta nke ọgwụgwọ psilocybin na ndị ọrịa na-aṅụ ọgwụ antidepressant SSRI omenala bụ nchọpụta dị oke mkpa ma anyị nwere obi ụtọ isonye na nchọpụta a dị mkpa."

"Ọtụtụ ndị Canada ndị na-alụso ịda mbà n'obi ọgụ na-enweta ọgwụgwọ SSRI, ma ruo ugbu a, nke a na-apụtakarị na a ga-ewepụ ya na ule ụlọ ọgwụ na-enyere aka psychedelic (PAP)," Josh Taylor, Onye guzobere Cybin Therapeutics kwuru. "Ọ bụrụ na enwere ike igosipụta na PAP nwere ike inye ndị ọrịa nọ na SSRI n'enweghị nsogbu, ọtụtụ ga-erite uru. Anyị na-eche na nke a bụ ohere pụtara ìhè igosi Health Canada na Cybin Therapeutics nwere ike imeziwanye nsonaazụ ndị ọrịa na ndị otu anyị wee mepụta ụkpụrụ. "

Filament nyekwara ikike PEX010 (25 mg) na CT maka ule ọzọ nke 2 nke ụlọ ọgwụ, nke a na-atụ anya ịmalite na nkeji nke anọ nke 2022. Dr. Reg Peters na Dave Phillips ga-eduzi ule abụọ ahụ.